{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 13,
  "pageCount": 29,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial stages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/13",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.65,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Key eligibility criteria -> Conditioning chemotherapy -> CRG-022 dose -> Follow-up period",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1913f57f-dcac-4218-ac72-0502a416f72e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.22,
        "x": 0.76,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Baseline Characteristics of Treated Patients (N=38)... Primary Endpoints... Key Secondary Endpoints",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ab1f5b5-54e3-487e-ab6e-c6ec38a3132b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Abbreviations: CAR19 = anti-CD19 CAR T-cell therapy; R/R = relapsed or refractory; CRG-022 = anti-CD22 CAR T-cell therapy; DL = dose level; RP2D = recommended phase 2 dose; TEAE = treatment-emergent adverse events; ORR = overall response rate; DOR = duration of response; PFS = progression free survival; OS = overall survival; ULN = upper limit of normal; Note: Response was classified according to Lugano criteria for LBCL; Source: Cheson BD, et al. J Clin Oncol. 2014; 32(27):3059-67; Lee DW, et al. Biol Blood Marrow Transplant. 2019; 25(4):625-38; Frank MJ et al. EHA 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11a80464-2ed5-41cd-8693-13050910d7dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1 design – Stanford study of CRG-022 CAR T in R/R LBCL",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a86b32b4-3bca-42c1-9aba-b59c8602965f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "efd709a1-b281-443f-93d4-5cc33550958a",
      "evidence": "Sequential flow of clinical trial stages",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 12,
      "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 12-15 present traction and results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06",
      "evidence": "The loop is opened on slide 10 and closed on slides 12-15",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}